 | • レポートコード：MRC2312MG01495 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、102ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療 |
| Single User | ￥487,500 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥731,250 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界のがん診断用リキッドバイオプシー市場規模と予測を収録しています。・世界のがん診断用リキッドバイオプシー市場：売上、2018年-2023年、2024年-2029年 ・世界のがん診断用リキッドバイオプシー市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界のがん診断用リキッドバイオプシー市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「血液検査」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 がん診断用リキッドバイオプシーのグローバル主要企業は、F. Hoffman La Roche Ltd.、 Thermo Fisher Scientific Inc.、 Agilent Technologies Inc.、 Illumina Inc.、 The Menarini Group、 Bio-Rad Laboratories Inc.、 QIAGEN Inc.、 Exact Sciences Corporation、 Bio-Techne Corporation、 ArcherDX Inc.、 Neogenomics Laboratories Inc.、 Guardant Health Inc.、 Myriad Genetics Inc.、 Foundation Medicine Inc.、 Amoy Diagnostics Co. Ltd.、 Biocartis Group NVなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、がん診断用リキッドバイオプシーのメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界のがん診断用リキッドバイオプシー市場：タイプ別、2018年-2023年、2024年-2029年 世界のがん診断用リキッドバイオプシー市場：タイプ別市場シェア、2022年 ・血液検査、尿検査、唾液検査 世界のがん診断用リキッドバイオプシー市場：用途別、2018年-2023年、2024年-2029年 世界のがん診断用リキッドバイオプシー市場：用途別市場シェア、2022年 ・病院、診断センター、その他 世界のがん診断用リキッドバイオプシー市場：地域・国別、2018年-2023年、2024年-2029年 世界のがん診断用リキッドバイオプシー市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業におけるがん診断用リキッドバイオプシーのグローバル売上、2018年-2023年 ・主要企業におけるがん診断用リキッドバイオプシーのグローバル売上シェア、2022年 ・主要企業におけるがん診断用リキッドバイオプシーのグローバル販売量、2018年-2023年 ・主要企業におけるがん診断用リキッドバイオプシーのグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 F. Hoffman La Roche Ltd.、 Thermo Fisher Scientific Inc.、 Agilent Technologies Inc.、 Illumina Inc.、 The Menarini Group、 Bio-Rad Laboratories Inc.、 QIAGEN Inc.、 Exact Sciences Corporation、 Bio-Techne Corporation、 ArcherDX Inc.、 Neogenomics Laboratories Inc.、 Guardant Health Inc.、 Myriad Genetics Inc.、 Foundation Medicine Inc.、 Amoy Diagnostics Co. Ltd.、 Biocartis Group NV ************************************************************* ・調査・分析レポートの概要 がん診断用リキッドバイオプシー市場の定義 市場セグメント 世界のがん診断用リキッドバイオプシー市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界のがん診断用リキッドバイオプシー市場規模 世界のがん診断用リキッドバイオプシー市場規模：2022年 VS 2029年 世界のがん診断用リキッドバイオプシー市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでのがん診断用リキッドバイオプシーの売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業のがん診断用リキッドバイオプシー製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：血液検査、尿検査、唾液検査 がん診断用リキッドバイオプシーのタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：病院、診断センター、その他 がん診断用リキッドバイオプシーの用途別グローバル売上・予測 ・地域別市場分析 地域別がん診断用リキッドバイオプシー市場規模 2022年と2029年 地域別がん診断用リキッドバイオプシー売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） F. Hoffman La Roche Ltd.、 Thermo Fisher Scientific Inc.、 Agilent Technologies Inc.、 Illumina Inc.、 The Menarini Group、 Bio-Rad Laboratories Inc.、 QIAGEN Inc.、 Exact Sciences Corporation、 Bio-Techne Corporation、 ArcherDX Inc.、 Neogenomics Laboratories Inc.、 Guardant Health Inc.、 Myriad Genetics Inc.、 Foundation Medicine Inc.、 Amoy Diagnostics Co. Ltd.、 Biocartis Group NV ... |
This research report provides a comprehensive analysis of the Liquid Biopsy For Cancer Diagnostics market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Liquid Biopsy For Cancer Diagnostics market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Liquid Biopsy For Cancer Diagnostics, challenges faced by the industry, and potential opportunities for market players.
The global Liquid Biopsy For Cancer Diagnostics market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Liquid Biopsy For Cancer Diagnostics market presents opportunities for various stakeholders, including Hospital, Diagnostic Center. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Liquid Biopsy For Cancer Diagnostics market. Additionally, the growing consumer demand present avenues for market expansion.
The global Liquid Biopsy For Cancer Diagnostics market was valued at US$ 3398.9 million in 2022 and is projected to reach US$ 7703.3 million by 2029, at a CAGR of 13.1% during the forecast period.
Researchers and developers continue to explore and expand the clinical utility of liquid biopsy. This includes investigating its application in various cancer types, different stages of cancer, and for monitoring treatment response and minimal residual disease.
Key Features:
The research report on the Liquid Biopsy For Cancer Diagnostics market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Liquid Biopsy For Cancer Diagnostics market.
Market Overview: The report provides a comprehensive overview of the Liquid Biopsy For Cancer Diagnostics market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Blood Test, Urine Test), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Liquid Biopsy For Cancer Diagnostics market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Liquid Biopsy For Cancer Diagnostics market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Liquid Biopsy For Cancer Diagnostics market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Liquid Biopsy For Cancer Diagnostics market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Liquid Biopsy For Cancer Diagnostics market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Liquid Biopsy For Cancer Diagnostics market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Liquid Biopsy For Cancer Diagnostics, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Liquid Biopsy For Cancer Diagnostics market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Liquid Biopsy For Cancer Diagnostics market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Blood Test
Urine Test
Saliva Test
Market segment by Application
Hospital
Diagnostic Center
Others
Global Liquid Biopsy For Cancer Diagnostics Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
F. Hoffman La Roche Ltd.
Thermo Fisher Scientific Inc.
Agilent Technologies Inc.
Illumina Inc.
The Menarini Group
Bio-Rad Laboratories Inc.
QIAGEN Inc.
Exact Sciences Corporation
Bio-Techne Corporation
ArcherDX Inc.
Neogenomics Laboratories Inc.
Guardant Health Inc.
Myriad Genetics Inc.
Foundation Medicine Inc.
Amoy Diagnostics Co. Ltd.
Biocartis Group NV
Outline of Major Chapters:
Chapter 1: Introduces the definition of Liquid Biopsy For Cancer Diagnostics, market overview.
Chapter 2: Global Liquid Biopsy For Cancer Diagnostics market size in revenue.
Chapter 3: Detailed analysis of Liquid Biopsy For Cancer Diagnostics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Liquid Biopsy For Cancer Diagnostics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Liquid Biopsy For Cancer Diagnostics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Liquid Biopsy For Cancer Diagnostics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Liquid Biopsy For Cancer Diagnostics Overall Market Size
2.1 Global Liquid Biopsy For Cancer Diagnostics Market Size: 2022 VS 2029
2.2 Global Liquid Biopsy For Cancer Diagnostics Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Liquid Biopsy For Cancer Diagnostics Players in Global Market
3.2 Top Global Liquid Biopsy For Cancer Diagnostics Companies Ranked by Revenue
3.3 Global Liquid Biopsy For Cancer Diagnostics Revenue by Companies
3.4 Top 3 and Top 5 Liquid Biopsy For Cancer Diagnostics Companies in Global Market, by Revenue in 2022
3.5 Global Companies Liquid Biopsy For Cancer Diagnostics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Liquid Biopsy For Cancer Diagnostics Players in Global Market
3.6.1 List of Global Tier 1 Liquid Biopsy For Cancer Diagnostics Companies
3.6.2 List of Global Tier 2 and Tier 3 Liquid Biopsy For Cancer Diagnostics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Liquid Biopsy For Cancer Diagnostics Market Size Markets, 2022 & 2029
4.1.2 Blood Test
4.1.3 Urine Test
4.1.4 Saliva Test
4.2 By Type – Global Liquid Biopsy For Cancer Diagnostics Revenue & Forecasts
4.2.1 By Type – Global Liquid Biopsy For Cancer Diagnostics Revenue, 2018-2023
4.2.2 By Type – Global Liquid Biopsy For Cancer Diagnostics Revenue, 2024-2029
4.2.3 By Type – Global Liquid Biopsy For Cancer Diagnostics Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Liquid Biopsy For Cancer Diagnostics Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Diagnostic Center
5.1.4 Others
5.2 By Application – Global Liquid Biopsy For Cancer Diagnostics Revenue & Forecasts
5.2.1 By Application – Global Liquid Biopsy For Cancer Diagnostics Revenue, 2018-2023
5.2.2 By Application – Global Liquid Biopsy For Cancer Diagnostics Revenue, 2024-2029
5.2.3 By Application – Global Liquid Biopsy For Cancer Diagnostics Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Liquid Biopsy For Cancer Diagnostics Market Size, 2022 & 2029
6.2 By Region – Global Liquid Biopsy For Cancer Diagnostics Revenue & Forecasts
6.2.1 By Region – Global Liquid Biopsy For Cancer Diagnostics Revenue, 2018-2023
6.2.2 By Region – Global Liquid Biopsy For Cancer Diagnostics Revenue, 2024-2029
6.2.3 By Region – Global Liquid Biopsy For Cancer Diagnostics Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Liquid Biopsy For Cancer Diagnostics Revenue, 2018-2029
6.3.2 US Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.3.3 Canada Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.3.4 Mexico Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Liquid Biopsy For Cancer Diagnostics Revenue, 2018-2029
6.4.2 Germany Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.4.3 France Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.4.4 U.K. Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.4.5 Italy Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.4.6 Russia Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.4.7 Nordic Countries Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.4.8 Benelux Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Liquid Biopsy For Cancer Diagnostics Revenue, 2018-2029
6.5.2 China Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.5.3 Japan Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.5.4 South Korea Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.5.5 Southeast Asia Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.5.6 India Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Liquid Biopsy For Cancer Diagnostics Revenue, 2018-2029
6.6.2 Brazil Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.6.3 Argentina Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Liquid Biopsy For Cancer Diagnostics Revenue, 2018-2029
6.7.2 Turkey Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.7.3 Israel Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.7.4 Saudi Arabia Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.7.5 UAE Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
7 Liquid Biopsy For Cancer Diagnostics Companies Profiles
7.1 F. Hoffman La Roche Ltd.
7.1.1 F. Hoffman La Roche Ltd. Company Summary
7.1.2 F. Hoffman La Roche Ltd. Business Overview
7.1.3 F. Hoffman La Roche Ltd. Liquid Biopsy For Cancer Diagnostics Major Product Offerings
7.1.4 F. Hoffman La Roche Ltd. Liquid Biopsy For Cancer Diagnostics Revenue in Global Market (2018-2023)
7.1.5 F. Hoffman La Roche Ltd. Key News & Latest Developments
7.2 Thermo Fisher Scientific Inc.
7.2.1 Thermo Fisher Scientific Inc. Company Summary
7.2.2 Thermo Fisher Scientific Inc. Business Overview
7.2.3 Thermo Fisher Scientific Inc. Liquid Biopsy For Cancer Diagnostics Major Product Offerings
7.2.4 Thermo Fisher Scientific Inc. Liquid Biopsy For Cancer Diagnostics Revenue in Global Market (2018-2023)
7.2.5 Thermo Fisher Scientific Inc. Key News & Latest Developments
7.3 Agilent Technologies Inc.
7.3.1 Agilent Technologies Inc. Company Summary
7.3.2 Agilent Technologies Inc. Business Overview
7.3.3 Agilent Technologies Inc. Liquid Biopsy For Cancer Diagnostics Major Product Offerings
7.3.4 Agilent Technologies Inc. Liquid Biopsy For Cancer Diagnostics Revenue in Global Market (2018-2023)
7.3.5 Agilent Technologies Inc. Key News & Latest Developments
7.4 Illumina Inc.
7.4.1 Illumina Inc. Company Summary
7.4.2 Illumina Inc. Business Overview
7.4.3 Illumina Inc. Liquid Biopsy For Cancer Diagnostics Major Product Offerings
7.4.4 Illumina Inc. Liquid Biopsy For Cancer Diagnostics Revenue in Global Market (2018-2023)
7.4.5 Illumina Inc. Key News & Latest Developments
7.5 The Menarini Group
7.5.1 The Menarini Group Company Summary
7.5.2 The Menarini Group Business Overview
7.5.3 The Menarini Group Liquid Biopsy For Cancer Diagnostics Major Product Offerings
7.5.4 The Menarini Group Liquid Biopsy For Cancer Diagnostics Revenue in Global Market (2018-2023)
7.5.5 The Menarini Group Key News & Latest Developments
7.6 Bio-Rad Laboratories Inc.
7.6.1 Bio-Rad Laboratories Inc. Company Summary
7.6.2 Bio-Rad Laboratories Inc. Business Overview
7.6.3 Bio-Rad Laboratories Inc. Liquid Biopsy For Cancer Diagnostics Major Product Offerings
7.6.4 Bio-Rad Laboratories Inc. Liquid Biopsy For Cancer Diagnostics Revenue in Global Market (2018-2023)
7.6.5 Bio-Rad Laboratories Inc. Key News & Latest Developments
7.7 QIAGEN Inc.
7.7.1 QIAGEN Inc. Company Summary
7.7.2 QIAGEN Inc. Business Overview
7.7.3 QIAGEN Inc. Liquid Biopsy For Cancer Diagnostics Major Product Offerings
7.7.4 QIAGEN Inc. Liquid Biopsy For Cancer Diagnostics Revenue in Global Market (2018-2023)
7.7.5 QIAGEN Inc. Key News & Latest Developments
7.8 Exact Sciences Corporation
7.8.1 Exact Sciences Corporation Company Summary
7.8.2 Exact Sciences Corporation Business Overview
7.8.3 Exact Sciences Corporation Liquid Biopsy For Cancer Diagnostics Major Product Offerings
7.8.4 Exact Sciences Corporation Liquid Biopsy For Cancer Diagnostics Revenue in Global Market (2018-2023)
7.8.5 Exact Sciences Corporation Key News & Latest Developments
7.9 Bio-Techne Corporation
7.9.1 Bio-Techne Corporation Company Summary
7.9.2 Bio-Techne Corporation Business Overview
7.9.3 Bio-Techne Corporation Liquid Biopsy For Cancer Diagnostics Major Product Offerings
7.9.4 Bio-Techne Corporation Liquid Biopsy For Cancer Diagnostics Revenue in Global Market (2018-2023)
7.9.5 Bio-Techne Corporation Key News & Latest Developments
7.10 ArcherDX Inc.
7.10.1 ArcherDX Inc. Company Summary
7.10.2 ArcherDX Inc. Business Overview
7.10.3 ArcherDX Inc. Liquid Biopsy For Cancer Diagnostics Major Product Offerings
7.10.4 ArcherDX Inc. Liquid Biopsy For Cancer Diagnostics Revenue in Global Market (2018-2023)
7.10.5 ArcherDX Inc. Key News & Latest Developments
7.11 Neogenomics Laboratories Inc.
7.11.1 Neogenomics Laboratories Inc. Company Summary
7.11.2 Neogenomics Laboratories Inc. Business Overview
7.11.3 Neogenomics Laboratories Inc. Liquid Biopsy For Cancer Diagnostics Major Product Offerings
7.11.4 Neogenomics Laboratories Inc. Liquid Biopsy For Cancer Diagnostics Revenue in Global Market (2018-2023)
7.11.5 Neogenomics Laboratories Inc. Key News & Latest Developments
7.12 Guardant Health Inc.
7.12.1 Guardant Health Inc. Company Summary
7.12.2 Guardant Health Inc. Business Overview
7.12.3 Guardant Health Inc. Liquid Biopsy For Cancer Diagnostics Major Product Offerings
7.12.4 Guardant Health Inc. Liquid Biopsy For Cancer Diagnostics Revenue in Global Market (2018-2023)
7.12.5 Guardant Health Inc. Key News & Latest Developments
7.13 Myriad Genetics Inc.
7.13.1 Myriad Genetics Inc. Company Summary
7.13.2 Myriad Genetics Inc. Business Overview
7.13.3 Myriad Genetics Inc. Liquid Biopsy For Cancer Diagnostics Major Product Offerings
7.13.4 Myriad Genetics Inc. Liquid Biopsy For Cancer Diagnostics Revenue in Global Market (2018-2023)
7.13.5 Myriad Genetics Inc. Key News & Latest Developments
7.14 Foundation Medicine Inc.
7.14.1 Foundation Medicine Inc. Company Summary
7.14.2 Foundation Medicine Inc. Business Overview
7.14.3 Foundation Medicine Inc. Liquid Biopsy For Cancer Diagnostics Major Product Offerings
7.14.4 Foundation Medicine Inc. Liquid Biopsy For Cancer Diagnostics Revenue in Global Market (2018-2023)
7.14.5 Foundation Medicine Inc. Key News & Latest Developments
7.15 Amoy Diagnostics Co. Ltd.
7.15.1 Amoy Diagnostics Co. Ltd. Company Summary
7.15.2 Amoy Diagnostics Co. Ltd. Business Overview
7.15.3 Amoy Diagnostics Co. Ltd. Liquid Biopsy For Cancer Diagnostics Major Product Offerings
7.15.4 Amoy Diagnostics Co. Ltd. Liquid Biopsy For Cancer Diagnostics Revenue in Global Market (2018-2023)
7.15.5 Amoy Diagnostics Co. Ltd. Key News & Latest Developments
7.16 Biocartis Group NV
7.16.1 Biocartis Group NV Company Summary
7.16.2 Biocartis Group NV Business Overview
7.16.3 Biocartis Group NV Liquid Biopsy For Cancer Diagnostics Major Product Offerings
7.16.4 Biocartis Group NV Liquid Biopsy For Cancer Diagnostics Revenue in Global Market (2018-2023)
7.16.5 Biocartis Group NV Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer